<div id="readability-page-1"><div><p>As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing over 3% amid improved geopolitical conditions, investors are keenly observing the small-cap segment for opportunities. In this environment of cautious optimism, identifying stocks that demonstrate strong fundamentals and potential insider confidence can be crucial in navigating the evolving market landscape.</p><h3>Top 10 Undervalued Small Caps With Insider Buying In Europe</h3><p> Click here to see the full list of 79 stocks from our Undervalued European Small Caps With Insider Buying screener.     </p><p>Let's take a closer look at a couple of our picks from the screened companies.</p><h2>Gubra (CPSE:GUBRA)</h2><p><strong>Simply Wall St Value Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Gubra is a company that specializes in contract research organization (CRO) services and biotechnology, with a focus on developing treatments for metabolic diseases, and has a market cap of DKK 1.96 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily from its Biotech segment, which significantly outpaces the CRO segment. Over recent periods, the gross profit margin has shown an upward trend, reaching 96.96% by December 2025. Operating expenses are largely driven by R&amp;D and General &amp; Administrative costs.</p><p><strong>PE:</strong> 3.4x</p><p>Gubra, a biotechnology company, has recently reported impressive financial results for 2025 with sales soaring to DKK 2.6 billion from DKK 265.74 million the previous year and net income reaching DKK 1.7 billion compared to a loss previously. However, earnings are expected to decline by an average of 37% annually over the next three years. The company has launched Gubra Ventures to foster biotech innovation while its clinical trial application for GUB-UCN2 aims at addressing obesity-related issues through innovative therapies. Despite high external borrowing risks, insider confidence is reflected in share purchases over recent months, indicating potential value recognition within this small-cap stock's strategic initiatives and growth prospects.</p><ul><li>Click here and access our complete valuation analysis report to understand the dynamics of Gubra.</li><li>Evaluate Gubra's historical performance by accessing our past performance report.</li></ul><h2>CellaVision (OM:CEVI)</h2><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> CellaVision is a Swedish company specializing in digital solutions for medical microscopy, primarily focusing on hematology, with a market capitalization of approximately SEK 7.50 billion.</p><p><strong>Operations:</strong> CellaVision generates revenue primarily through its sales, with recent figures showing SEK 758.97 million in revenue. The company's gross profit margin has shown fluctuations, recently recorded at 68.50%. Operating expenses include significant allocations toward sales and marketing, as well as research and development efforts.</p><p><strong>PE:</strong> 24.9x</p><p>CellaVision, a player in the digital cell morphology industry, recently launched its Bone Marrow Aspirate Application across EMEA, enhancing diagnostic capabilities for blood diseases. The application’s CE marking underlines its compliance with EU safety standards. Financially, CellaVision's sales rose to SEK 759 million in 2025 from SEK 723 million the previous year, while net income increased to SEK 153 million. Insider confidence is evident as Christer Fahraeus acquired shares worth approximately US$15.69 million this year.</p><ul><li>Get an in-depth perspective on CellaVision's performance by reading our valuation report here.</li><li>Review our historical performance report to gain insights into CellaVision's's past performance.</li></ul><h2>Karnov Group (OM:KAR)</h2><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Karnov Group is a provider of legal and tax information services, with operations primarily in the Nordic region and a market capitalization of SEK 4.28 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily from Region North and Region South, with recent figures indicating SEK 1.32 billion and SEK 1.32 billion respectively. Over the observed periods, its gross profit margin has shown variability, reaching as high as 52.99% in the past but most recently recorded at 43.65%. Operating expenses have fluctuated significantly, impacting net income margins which have varied widely from negative to positive values over time.</p><p><strong>PE:</strong> 7.6x</p><p>Karnov Group, a player in the European market, has been actively reshaping its financial landscape. Recently, they announced an increase in their equity buyback plan to SEK 750 million as of March 25, 2026. This move aims to optimize capital structure and enhance shareholder value. Despite a forecasted earnings decline of nearly 30% annually over the next three years, insider confidence remains evident through significant share repurchases. The company posted a net income of SEK 970 million for the full year ending December 2025, reversing from a previous loss.</p><ul><li>Navigate through the intricacies of Karnov Group with our comprehensive valuation report here.</li><li>Assess Karnov Group's past performance with our detailed historical performance reports.</li></ul><h2>Taking Advantage</h2><ul><li>Dive into all 79 of the Undervalued European Small Caps With Insider Buying we have identified here.</li><li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li><li>Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.</li></ul><h2>Seeking Other Investments?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

ABCL

FPXE

LABU

SBIO

<p>As European markets rise, investors are focusing on undervalued small-cap stocks with insider buying. Notable companies include Gubra, a biotech firm with a market cap of DKK 1.96 billion, reporting significant revenue growth but expected earnings decline. CellaVision, specializing in medical microscopy, shows strong sales and insider confidence with a recent share purchase. Karnov Group, providing legal information services, has increased its equity buyback plan to SEK 750 million despite a forecasted earnings decline. These companies reflect potential investment opportunities in the evolving market landscape.</p>

Top European Undervalued Small Caps With Insider Action In April 2026